Anticancer agent 45_product_DataBase

Bioactivity	Anticancer agent 46 (compound 2b) is a potent and selective anticancer agent. Anticancer agent 46 shows cytotoxicity activity in cancer cells. Anticancer agent 46 induces apoptosis. Anticancer agent 46 shows low toxicity towards activated lymphocytes of human blood[1].
Invitro	Anticancer agent 46 (compound 2b) (0-100 µM; 72 h) shows antitumor activity with GI50S of 1.30, 7.25, 4.00, 6.20, 8.00, 6.13, 4.52, 5.65, 1.10, >100, 73.62 µM for Jurkat, A549, MCF-7, MDA-MB-231, KB3-1, HeLa, HCT-116, HCT-116 p53-/-, U251, SK-OV-3, HaCaT cells, respectively[1].Anticancer agent 46 (1.5 µM; 24 h) induces apoptosis by increases the expression of caspase 3, Bax and decreases the amount of anti-apoptotic Bcl-2 protein[1].Anticancer agent 46 (compound 2b) (0-2 µM; 24, 48 h) shows low toxicity towards normal human keratinocytes of HaCaT line and mitogen-activated lymphocytes of peripheral blood of healthy human donor[1].Anticancer agent 46 dose not induce significant DNA damage and changes in morphology of mitogen-activated lymphocytes of peripheral blood of healthy donor[1]. Western Blot Analysis[1] Cell Line:
Name	Anticancer agent 45
Formula	C22H14ClN3O6S2
Molar Mass	515.95
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

PeptideDB